% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wansch:307496,
      author       = {K. Wansch and F. Schneider and F. Dölvers and A. Kühn and
                      M. P. Dragomir$^*$ and M. Joosten and G. Hilfenhaus and L.
                      Vecchione and M. Felsenstein and M. Lerchbaumer and C.
                      Jürgensen and M. Bahra and G. Duwe and R. Schäfer and S.
                      Stintzing and U. Keilholz and C. C. M. Neumann and U.
                      Pelzer},
      title        = {{I}dentifying {F}actors of {O}rganoid {E}stablishment in
                      {P}ancreatic {C}ancer: {A} {P}rospective {O}bservational
                      {S}tudy.},
      journal      = {Cancer medicine},
      volume       = {15},
      number       = {1},
      issn         = {2045-7634},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2026-00001},
      pages        = {e71490},
      year         = {2026},
      note         = {#DKTKZFB26#},
      abstract     = {Patient-derived organoid (PDO) models have emerged as
                      critical tools in pancreatic ductal adenocarcinoma (PDAC)
                      research and are used as surrogates for studying the
                      individual's tumor biology. Still, PDO-based concepts for
                      direct clinical application remain challenging. In this
                      prospective observational trial (OrgaPanCCC-01), we aim to
                      address clinical feasibility, identify predictive factors
                      for PDO establishment, and assess the prognostic potential
                      of PDO establishment for patient's survival.Samples for PDO
                      generation were prospectively collected via endoscopy,
                      surgery, and transcutaneous punch biopsy, or from ascites.
                      Patients were followed up for a median time of 14.6 months.
                      We evaluated the clinical feasibility by determining the PDO
                      establishment rate and the time required for establishment.
                      Uni- and multivariate analyses were performed to examine the
                      effect of clinical and sample characteristics on PDO
                      establishment. For the predictive and prognostic potential,
                      PDO establishment was correlated to the patients'
                      disease-free (DFS), progression-free (PFS) and overall
                      survival (OS).Between 2021 and 2023, 75 patients were
                      enrolled with radiologically suspected PDAC at the Charité
                      Universitätsmedizin Berlin and at the Waldfriede
                      Krankenhaus Berlin. PDAC was confirmed in 62 patients
                      $(83\%).$ PDO establishment was achieved in $58\%$ (n =
                      36/62) of patients within a median of 28 days, supporting
                      the feasibility of clinical implementation. In the uni- and
                      multivariate analysis, samples from metastatic sites (p =
                      0.04) and higher CA19-9 levels (p = 0.03) were found to be
                      positively correlated with PDO growth. Patients without PDO
                      growth tended to have longer PFS (p = 0.32), whereas no
                      statistically significant correlation was observed between
                      PDO growth and OS.In this prospective observational trial,
                      we show that PDO generation is feasible at a success rate of
                      $58\%$ within a clinically reasonable time frame of 6 weeks.
                      The efficacy of PDO establishment depended on sample site,
                      with metastatic samples showing higher establishment rates.
                      Higher CA 19-9 levels were positively correlated with PDO
                      growth. Successful PDO establishment did not have a
                      prognostic value for OS. Overall, our findings underline the
                      great potential of PDO-based precision medicine approaches,
                      which should further be evaluated in prospective
                      interventional translational trials.},
      keywords     = {Humans / Pancreatic Neoplasms: pathology / Pancreatic
                      Neoplasms: mortality / Pancreatic Neoplasms: therapy / Male
                      / Female / Organoids: pathology / Prospective Studies /
                      Middle Aged / Aged / Carcinoma, Pancreatic Ductal: pathology
                      / Carcinoma, Pancreatic Ductal: mortality / Prognosis /
                      Feasibility Studies / Adult / Aged, 80 and over / functional
                      precision medicine (Other) / pancreatic ductal
                      adenocarcinoma (Other) / patient‐derived organoids
                      (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41469727},
      pmc          = {pmc:PMC12753581},
      doi          = {10.1002/cam4.71490},
      url          = {https://inrepo02.dkfz.de/record/307496},
}